Adverse reactions to voriconazole

被引：141

作者：

Boyd, AE

Modi, S

Howard, SJ

Moore, CB

Keevil, BG

Denning, DW

机构：

[1] Wythenshawe Hosp, Educ & Res Ctr, Manchester M23 9LT, Lancs, England

[2] Wythenshawe Hosp, Dept Clin Biochem, Manchester M23 9LT, Lancs, England

[3] Hope Hosp, Antifungal Testing Lab, Manchester, Lancs, England

[4] N Manchester Grp Hosp, Dept Infect Dis & Trop Med, Manchester, Lancs, England

[5] Univ Manchester, Manchester M13 9PL, Lancs, England

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 39卷 / 08期

基金：

英国惠康基金;

关键词：

D O I：

10.1086/424662

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Voriconazole is a new antifungal agent effective in the treatment of invasive aspergillosis. Interpatient variation in plasma concentrations is considerable-more than 100-fold. We describe 3 patients with diverse manifestations of toxicity ( e. g., hallucinations, hypoglycemia, electrolyte disturbance, and pneumonitis) possibly attributable to high voriconazole concentrations. Measurement of plasma concentrations could be helpful in optimizing voriconazole dosages.

引用

收藏

页码：1241 / 1244

页数：4

相关论文

共 8 条

[1] THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN METABOLISM - A POPULATION STUDY [J].

BALIAN, JD ;

SUKHOVA, N ;

HARRIS, JW ;

HEWETT, J ;

PICKLE, L ;

GOLDSTEIN, JA ;

WOOSLEY, RL ;

FLOCKHART, DA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) :662-669

[2] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].

Denning, DW ;

Ribaud, P ;

Milpied, N ;

Caillot, D ;

Herbrecht, R ;

Thiel, E ;

Haas, A ;

Ruhnke, M ;

Lode, H .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571

[3] Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole [J].

Denning, DW ;

Griffiths, CEM .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (08) :648-653

[4] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[5]

KEEVIL B, IN PRESS THERAP DRUG

[6] Safety of voriconazole and dose individualization [J].

Lutsar, I ;

Hodges, MR ;

Tomaszewski, K ;

Troke, PF ;

Wood, ND .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) :1087-1088

[7] Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma [J].

Perea, S ;

Pennick, GJ ;

Modak, A ;

Fothergill, AW ;

Sutton, DA ;

Sheehan, DJ ;

Rinaldi, MG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (05) :1209-1213

[8]

*US FDA, 2001, ANT DRUGS ANDV COMM